Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Add shares to your
quickpicks to
display them here!

Reneuron (RENE)

Price 7.00p on 25-09-2023 at 03:45:10
Change 0.00p 0%
Buy 7.50p
Sell 6.50p
Buy / Sell RENE Shares
Last Trade: Buy 10,000.00 at 7.18p
Day's Volume: 0
Last Close: 7.00p
Open: 0.00p
Day's Range 0.00p - 0.00p
52wk Range: 5.55p - 29.00p
Market Capitalisation: £4m
VWAP: 0.00p
Shares in Issue: 57m

Recent Trades History Reneuron (RENE)

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 10,000 7.18p Ordinary
13:53:29 - 22-Sep-23
Sell* 2,000 6.50p Ordinary
13:48:27 - 22-Sep-23
Buy* 10,000 7.18p Ordinary
12:35:28 - 22-Sep-23
Buy* 50,000 7.20p Ordinary
11:27:23 - 22-Sep-23
Unknown* 1,795 7.00p Ordinary
08:09:44 - 22-Sep-23

Share Price History for Reneuron

Time period:
Date Open High Low Close Volume

Share News for Reneuron

IN BRIEF: ReNeuron makes progress on exosome delivery platform

4th Sep 2023 10:24

ReNeuron Group PLC - Brigend, Wales-based stem cell and exosomes technology company - Generates in vivo data to exemplify cellular and tissue targeting capabilities of exosomes, produced from its multiple conditionally immortalised producer cell lines. Exosomes are extracellular vesicles which carry nucleic acids, proteins, lipids and metabolites. Typically, they play important roles in immune response, tumour progression, and neurodegenerative diseases. Read More

UK shareholder meetings calendar - next 7 days

15th Aug 2023 15:45

Read More

UK earnings, trading statements calendar - next 7 days

18th May 2023 15:03

Read More

IN BRIEF: ReNeuron reduces headcount by 40%; to focus on CustomEX data

19th Jan 2023 14:29

ReNeuron Group PLC - Bridgend, Wales-based stem cell and exosomes technology company - Says it has reduced its headcount by 40% following company restructuring. The company says variable costs of the business have been lowered, with the resulting cash runway now extending to 2024. ReNeuron says its focus is generating in vivo data to validate its exosome delivery technology platform, CustomEx. CustomEx is a drug delivery platform which can be optimised for specific tissue targets leading to improvements in outcome for the patient. Read More

ReNeuron Chair Iain Ross moves to executive chair as CEO departs

3rd Jan 2023 11:21

(Alliance News) - ReNeuron Group PLC on Tuesday said its chief executive officer has left immediately, replaced by an executive chair. Read More

FTSE 100 Latest

Login to your account

Forgot Password?

Not Registered